Havrix Junior

Havrix Junior is a pediatric hepatitis A vaccine that contains inactivated hepatitis A virus antigen combined with the adjuvant algeldrate. It is supplied as an injectable solution for intramuscular administration. The product is authorized in the European Union and is available by prescription only. Havrix Junior is formulated to induce active immunity against hepatitis A infection in children, providing a safe and effective preventive measure.

Havrix Junior is indicated for the active immunization of children against hepatitis A virus infection.

- Administration to children aged 12 months and older as part of a primary vaccination series. - Use in combination with other routine childhood vaccines when schedule permits. - Providing protection in regions with intermediate or high hepatitis A endemicity. - Supporting travel health recommendations for pediatric travelers to areas with hepatitis A risk. - Facilitating outbreak control measures in school or community settings.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Injection site pain, redness or swelling. - Mild fever. - Headache. - Fatigue.

Serious: - Severe allergic reaction (anaphylaxis). - High fever lasting more than 48 hours. - Neurological symptoms such as seizures (rare).

Before administering Havrix Junior, healthcare providers should review the child’s medical history and consider specific safety considerations.

- Known hypersensitivity to any vaccine component, including algeldrate, should contraindicate use. - Post‑vaccination fever may require antipyretic treatment. - Delay vaccination in children with acute moderate or severe illness. - Observe the child for at least 15 minutes after injection for immediate reactions. - Consult a physician for children with compromised immune systems. - Pregnancy considerations are not applicable to the pediatric target group but should be noted for future planning.

Havrix Junior may interact with other agents that affect immune function or increase the risk of hypersensitivity.

Avoid: - Live attenuated vaccines administered within 4 weeks before or after Havrix Junior. - Immunoglobulin products given concurrently, which may reduce vaccine response.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids) that could diminish antibody formation. - Antipyretic or analgesic medications taken prophylactically may mask mild post‑vaccination symptoms.